Peter Lawson

Stock Analyst at Barclays

(0)
# 4551
Out of 5,240 analysts
124
Total ratings
31.08%
Success rate
-15.47%
Average return
40 Stocks
Name Action Price Target Current % Upside Ratings Updated
Biomea Fusion
Maintains: Equal-Weight
9 11
4.16 164.42% 4 Oct 30, 2024
Arcus Biosciences
Maintains: Overweight
25 29
13.79 110.3% 6 Oct 25, 2024
Revolution Medicines
Maintains: Overweight
54 60
39.85 50.56% 3 Sep 27, 2024
Relay Therapeutics
Maintains: Overweight
14 17
4.37 289.02% 5 Sep 10, 2024
Syndax Pharmaceutica...
Maintains: Overweight
32 33
12.61 161.7% 4 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
5
n/a n/a 4 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
92 66
28.5 131.58% 2 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 8
3.04 163.16% 8 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
60 48
17.2 179.07% 6 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
75 105
102.53 2.41% 10 Jul 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 31
18.56 67.03% 2 Jul 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
13 17
10.49 62.06% 3 Jun 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
18 13
2.62 396.18% 1 May 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Equal-Weight
9 26
n/a n/a 6 Apr 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
25 25
35.65 -29.87% 4 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
7 9
2.62 243.51% 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
18 22
5.89 273.51% 5 Feb 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
47 63
32.49 93.91% 3 Feb 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
6 10
1.25 700% 3 Feb 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
27 31
n/a n/a 6 Dec 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
2 1
0.59 69.49% 2 Aug 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
7 5
1.01 395.05% 4 Aug 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
175 50
0.1 49900% 2 Aug 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
14 8
0.64 1150% 2 Aug 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
30
14.82 102.43% 1 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
7 4
0.85 311.76% 4 Jul 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
355 365
136.28 167.83% 1 Aug 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
46
33.33 38.01% 2 Oct 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
40
n/a n/a 1 May 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
30
0.9 3233.33% 1 Mar 4, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
33
n/a n/a 1 Mar 4, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Underweight
28
19.15 46.21% 1 Mar 4, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
65 75
n/a n/a 2 Dec 4, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
49
n/a n/a 1 May 31, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
21
n/a n/a 1 Apr 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
19 5
n/a n/a 4 Apr 9, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
16 45
38.34 17.37% 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
17 45
1.14 3847.37% 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 3 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
70
1.05 6566.67% 1 Jul 14, 2017